Corinne Johnson
Stock Analyst at Goldman Sachs
(2.71)
# 2,136
Out of 4,969 analysts
12
Total ratings
54.55%
Success rate
6.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Avidity Biosciences | Reinstates: Buy | $55 | $47.59 | +15.57% | 2 | Jul 10, 2025 | |
| AVBP ArriVent BioPharma | Reinstates: Buy | $33 | $19.26 | +71.34% | 3 | Jul 10, 2025 | |
| AMLX Amylyx Pharmaceuticals | Reinstates: Buy | $10 | $9.84 | +1.63% | 1 | Jul 10, 2025 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $18 | $16.13 | +11.59% | 1 | Jul 10, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $182 | $136.11 | +33.72% | 1 | Jul 10, 2025 | |
| CGON CG Oncology | Upgrades: Buy | $43 → $50 | $28.67 | +74.40% | 3 | May 14, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $16.70 | +199.40% | 1 | Mar 13, 2024 |
Avidity Biosciences
Jul 10, 2025
Reinstates: Buy
Price Target: $55
Current: $47.59
Upside: +15.57%
ArriVent BioPharma
Jul 10, 2025
Reinstates: Buy
Price Target: $33
Current: $19.26
Upside: +71.34%
Amylyx Pharmaceuticals
Jul 10, 2025
Reinstates: Buy
Price Target: $10
Current: $9.84
Upside: +1.63%
Syndax Pharmaceuticals
Jul 10, 2025
Initiates: Buy
Price Target: $18
Current: $16.13
Upside: +11.59%
Neurocrine Biosciences
Jul 10, 2025
Initiates: Buy
Price Target: $182
Current: $136.11
Upside: +33.72%
CG Oncology
May 14, 2024
Upgrades: Buy
Price Target: $43 → $50
Current: $28.67
Upside: +74.40%
Immunovant
Mar 13, 2024
Initiates: Buy
Price Target: $50
Current: $16.70
Upside: +199.40%